[go: up one dir, main page]

ECSP19026178A - Anticuerpos anti-pd-1 y sus usos - Google Patents

Anticuerpos anti-pd-1 y sus usos

Info

Publication number
ECSP19026178A
ECSP19026178A ECSENADI201926178A ECDI201926178A ECSP19026178A EC SP19026178 A ECSP19026178 A EC SP19026178A EC SENADI201926178 A ECSENADI201926178 A EC SENADI201926178A EC DI201926178 A ECDI201926178 A EC DI201926178A EC SP19026178 A ECSP19026178 A EC SP19026178A
Authority
EC
Ecuador
Prior art keywords
antibodies
manufacture
present disclosure
methods
nucleic acids
Prior art date
Application number
ECSENADI201926178A
Other languages
English (en)
Inventor
Daniel E H Afar
Josue Samayoa
Fiona A Harding
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of ECSP19026178A publication Critical patent/ECSP19026178A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente divulgación provee nuevos anticuerpos anti-PD-1, composiciones que incluyen los nuevos anticuerpos, ácidos nucleicos que codifican los anticuerpos, y métodos para la elaboración y uso de los mismos.
ECSENADI201926178A 2016-09-14 2019-04-12 Anticuerpos anti-pd-1 y sus usos ECSP19026178A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394314P 2016-09-14 2016-09-14

Publications (1)

Publication Number Publication Date
ECSP19026178A true ECSP19026178A (es) 2019-04-30

Family

ID=59955732

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201926178A ECSP19026178A (es) 2016-09-14 2019-04-12 Anticuerpos anti-pd-1 y sus usos

Country Status (34)

Country Link
US (4) US9914783B1 (es)
EP (2) EP3778643A1 (es)
JP (1) JP7079773B2 (es)
KR (2) KR102561356B1 (es)
CN (1) CN109789205B (es)
AU (1) AU2017326329B2 (es)
BR (1) BR112019004998A2 (es)
CA (1) CA3035932A1 (es)
CL (2) CL2019000628A1 (es)
CO (1) CO2019003154A2 (es)
CR (1) CR20190199A (es)
CY (1) CY1123642T1 (es)
DK (1) DK3512547T3 (es)
DO (1) DOP2019000056A (es)
EC (1) ECSP19026178A (es)
ES (1) ES2837755T3 (es)
HR (1) HRP20201993T1 (es)
HU (1) HUE051700T2 (es)
IL (2) IL306104A (es)
LT (1) LT3512547T (es)
MX (1) MX2019002946A (es)
MY (1) MY192158A (es)
PE (1) PE20191102A1 (es)
PH (1) PH12019500540A1 (es)
PL (1) PL3512547T3 (es)
PT (1) PT3512547T (es)
RS (1) RS61204B1 (es)
RU (1) RU2752562C2 (es)
SG (1) SG10201914120XA (es)
SI (1) SI3512547T1 (es)
SM (1) SMT202000691T1 (es)
UA (1) UA124631C2 (es)
WO (1) WO2018053106A1 (es)
ZA (1) ZA201902265B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
MA42459A (fr) 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
AU2016355570B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
PE20191102A1 (es) * 2016-09-14 2019-08-23 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
CN110291109B (zh) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
KR102692379B1 (ko) 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
CN111836887A (zh) 2018-01-08 2020-10-27 艾欧凡斯生物治疗公司 产生富含肿瘤抗原特异性t细胞的til产品的方法
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
RU2020129827A (ru) 2018-02-13 2022-03-14 Мерк Шарп И Доум Корп. Способы лечения злокачественного новообразования с использованием антител против pd-1
KR20210005138A (ko) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도
JP7520806B2 (ja) 2018-07-15 2024-07-23 レノヴァロ バイオファーマ インコーポレイテッド がん治療のための組換え樹状細胞を使用する方法及び組成物
JP7519985B2 (ja) 2018-07-19 2024-07-22 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体、投薬量、およびその使用
US20220090018A1 (en) 2018-11-05 2022-03-24 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and used of the same in immunotherapy
JP2022514702A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
CA3124408A1 (en) * 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
SG11202106347PA (en) 2018-12-21 2021-07-29 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US12303521B2 (en) 2019-02-18 2025-05-20 Medivir Ab Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
EP3931349B8 (en) * 2019-02-28 2025-01-15 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JPWO2021025140A1 (es) 2019-08-08 2021-02-11
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
JP2023514056A (ja) * 2020-02-07 2023-04-05 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用した癌の治療レジメン
CA3191749A1 (en) * 2020-08-31 2022-03-03 Biosion Inc. Pd-1 binding antibodies and uses thereof
CA3197951A1 (en) * 2020-11-11 2022-05-19 Ugur Sahin Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
AU2021402065A1 (en) 2020-12-17 2023-06-29 Boehringer Ingelheim International Gmbh Bifunctional anti-pd1/il-7 molecules
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
US20240150487A1 (en) * 2022-03-04 2024-05-09 Trishula Therapeutics Inc. Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
CN119907811A (zh) 2022-08-02 2025-04-29 Ose免疫疗法公司 针对cd28的多功能分子
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
US20250059280A1 (en) 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
AU2002338272B2 (en) 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2003006636A1 (de) 2001-07-12 2003-01-23 Genethor Gmbh Reduktion der stimulationsfähigkeit von antigen präsentierenden zellen
ATE524495T1 (de) 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
SI2206517T1 (sl) 2002-07-03 2023-12-29 Ono Pharmaceutical Co., Ltd. Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
KR20080000613A (ko) 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
NZ626867A (en) * 2006-12-27 2014-09-26 Harvard College Compositions and methods for the treatment of infections and tumors
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009288730B2 (en) * 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
WO2014105810A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
AU2014233528B2 (en) 2013-03-15 2019-02-28 Abbvie Biotherapeutics Inc. Fc variants
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US20160031990A1 (en) 2014-05-29 2016-02-04 Medlmmune, Llc Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
EP3215538A4 (en) * 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
WO2016106159A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
KR20230012070A (ko) 2016-03-21 2023-01-25 데이비드 비. 웨이너 Dna 항체 작제물 및 이의 사용 방법
PE20191102A1 (es) * 2016-09-14 2019-08-23 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos

Also Published As

Publication number Publication date
CN109789205A (zh) 2019-05-21
RU2019110835A (ru) 2020-10-15
DOP2019000056A (es) 2019-06-16
CL2019003627A1 (es) 2020-04-24
IL306104A (en) 2023-11-01
SMT202000691T1 (it) 2021-01-05
ZA201902265B (en) 2021-10-27
NZ751202A (en) 2023-10-27
EP3778643A1 (en) 2021-02-17
MX2019002946A (es) 2019-09-26
PL3512547T3 (pl) 2021-03-08
CR20190199A (es) 2019-08-27
CL2019000628A1 (es) 2019-06-07
AU2017326329B2 (en) 2023-10-26
KR20230114331A (ko) 2023-08-01
CA3035932A1 (en) 2018-03-22
DK3512547T3 (en) 2020-12-07
UA124631C2 (uk) 2021-10-20
HUE051700T2 (hu) 2021-03-29
WO2018053106A1 (en) 2018-03-22
CN109789205B (zh) 2022-12-13
US20180148513A1 (en) 2018-05-31
PT3512547T (pt) 2020-12-11
KR20190045938A (ko) 2019-05-03
EP3512547A1 (en) 2019-07-24
RU2019110835A3 (es) 2021-01-26
LT3512547T (lt) 2021-01-11
IL265179B1 (en) 2023-10-01
PE20191102A1 (es) 2019-08-23
JP7079773B2 (ja) 2022-06-02
CO2019003154A2 (es) 2019-05-21
US9914783B1 (en) 2018-03-13
SG10201914120XA (en) 2020-03-30
CY1123642T1 (el) 2022-03-24
US20180072810A1 (en) 2018-03-15
HRP20201993T1 (hr) 2021-02-05
BR112019004998A2 (pt) 2019-06-04
EP3512547B1 (en) 2020-11-11
RS61204B1 (sr) 2021-01-29
ES2837755T3 (es) 2021-07-01
JP2019533989A (ja) 2019-11-28
AU2017326329A1 (en) 2019-03-21
RU2752562C2 (ru) 2021-07-29
US20200317808A1 (en) 2020-10-08
US10730953B2 (en) 2020-08-04
SI3512547T1 (sl) 2021-01-29
MY192158A (en) 2022-08-03
IL265179A (en) 2019-05-30
PH12019500540A1 (en) 2019-10-28
KR102561356B1 (ko) 2023-08-03
IL265179B2 (en) 2024-02-01
US20200040098A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
ECSP17023281A (es) Inhibidores de mk2 y sus usos
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CR20150462A (es) Inhibidores de erk y sus usos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2019004690A (es) Constructos de anticuerpos.
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos